Cognate BioServices, Inc., the premier commercial-ready, global CDMO in the Cell and Gene Therapy industry, announced today its plans to expand cell and gene therapy manufacturing capacity, laboratory space, warehousing capabilities, and increase office support at its...
MEMPHIS, Tenn., January 21, 2019 /PRNewswire/ — Cognate BioServices, a leading contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated...
Read More
Providing large scale manufacturing capacity for AZD1222 KEELE, United Kingdom, June 16, 2020 /PRNewswire/ — Cobra Biologics (Cobra), part of the Cognate BioServices family,...
Read More
Cognate BioServices announces acquisition of Cobra Biologics Transformative acquisition creates global cell and gene therapy manufacturing services platform for both...
Read More
Cognate BioServices Secures Growth Capital Investment from EW Healthcare to Continue to Expand Commercial Manufacturing Capacity and Services for the Cellular Therapies Industry ...
Read More